Pfizer will buy Anacor Pharmaceuticals in a deal valued at $5.2 billion, for access to Anacor's non-steroidal topical gel to treat eczema. » Read More
In less than two weeks, there've been four pretty significant events in biopharma. And, hopefully, after ADA things will begin to settle down a bit for the summer.
How much higher do we need to go before the bears believe this rally is real?
The cost of drugs was a hot topic at ASCO this year, especially with the release of the big test results combining two very expensive treatments for lung cancer. The study showed using Avastin from Roche and Genentech and a pill, Tarceva, from OSI Pharmaceuticals, Roche and Genentech slowed down progression of the disease by a little more than a month.
The Dow Industrials briefly turned positive for the year earlier this morning. WAHOO! But wait…the S&P 500 turned positive for 2009 nearly one month ago and is now up over 4.5% this year. So why the performance lag in the Dow (compared to the S&P)?
With the exit of Citigroup and GM from the Dow, new comers Cisco and Travelers bring some heft back into the index. As of Monday's close, the price weighted index is taking out $4.44 (combined price of Citi and GM) and adding in $61.41 (CSCO + TRV). Here's how this change will impact the weight of the remaining 28 stocks of the Dow.
We are putting cash back to work, said Ron Muhlenkamp, portfolio manager at The Muhlenkamp Fund, and Jeff Mortimer, CIO of Charles Schwab Investment Management.
How will male General Motors retirees get their motor runnin'? Do they start paying for their impotence drugs out of their own pocket? Because apparently, under the new deal the company won't pick up the tab anymore.
Consumers may be saving more and spending less, but big pharma is on a shopping spree. And I'm not talking about the really big deals including Roche buying Genentech, Pfizer buying Wyeth and Merck buying Schering-Plough. I'm talking about the two deals that have been done in less than a week between major drug companies and baby biotechs specializing in oncology.
One year after urging regulators to guide Lehman Brothers toward a recapitalization and recognition of its losses, hedge fund manager David Einhorn is making more potentially prescient speeches—this time about ratings agencies and gold.
Plus, Cramer explains why First Niagara is just the type of bank that investors want right now.
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
Hewlett Packard reported earnings after the bell yesterday, and met analyst expectations. All 30 Dow stocks have now reported -- here is a summary of how the season stacked up.
Kirk Kerkorian and Warren Buffett are two more of the world’s richest investors who have just revealed how they’re gaming stocks!
Following are the day’s biggest winners and losers. Find out why shares of CME Group and Philip Morris popped while Ford and Citigroup dropped.
Market Trivia Question: Which four stocks have more than doubled since the market’s current low back in March? As investors debate whether the market rally still "has legs," four Dow components have more than doubled since the Dow hit a multi-year low.
Pfizer Chairman and CEO Jeff Kindler last year repeatedly said big deals in big pharma don't work. But, he added, he'd never say never. And sure enough, this year Kindler's buying Wyeth.
This takes the prize for the most dangerously optimistic acronym for a clinical trial. But MADIT (pronounced "made it") made it. Some folks with a lot of chutzpah at Guidant, now owned by Boston Scientific, apparently came up with the name for their big studies on implantable cardio defibrillators.
Stocks rose on Thursday, snapping a two-day losing streak, as investors gave techs another go and Wal-Mart hit its earnings target. However, some economic reports that missed expectations curbed gains. Experts weighed in on the markets, the commercial real estate, and more...
Stocks lost more than 2% Wednesday as bank shares continued to struggle and retail sales unexpectedly fell for a second straight month.
A gloomy sales report dragged down investor sentiment on Wednesday sending the S&P 500 to its third straight day of declines.